Regulation of autoimmune disease by natural killer T cells

Journal of Molecular Medicine

Volumn 80, Issue 5, 2002, Pages 290-300

  Sharif, Shayan ^a   Arreaza, Guillermo A ^a   Zucker, Peter ^a   Mi, Qing Sheng ^a   Delovitch, Terry L ^a,b,c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

Galactosylceramide; Autoimmune type I diabetes; CD1d; Immunoregulatory cells; NOD

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CHEMOKINE; CYTOKINE; GLYCOLIPID; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL ASSAY; CELL COUNT; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL TRANSFER; CELL TRANSPLANTATION; CELL TYPE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE PREDISPOSITION; EFFECTOR CELL; HUMAN; IMMUNOREGULATION; LYMPHOID ORGAN; MICROBIAL IMMUNITY; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; HOMEOSTASIS; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS;

ANIMAL; AUTOIMMUNE DISEASES; DIABETES MELLITUS, INSULIN-DEPENDENT; HOMEOSTASIS; HUMAN; KILLER CELLS, NATURAL; SUPPORT, NON-U.S. GOV'T; ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS;

EID: 0036012796     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-002-0332-8     Document Type: Review

References (113)

1. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD
2. Role of regulatory T cells in the pathogenesis of autoimmune diabetes
3. Mouse CD1-specific NK1 T cells: Development, specificity, and function
4. Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove
5. Essential requirement of an invariant V alpha 14 T cell antigen receptor expression in the development of natural killer T cells
6. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain
7. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells
8. NKT cells are phenotypically and functionally diverse
9. Phenotypic characterization of CD8 (+) NKT cells
10. Emergence of CD8+ T cells expressing NK cell receptors in influenza A virus-infected mice
11. CD1d-restricted NKT cells: An interstrain comparison
12. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
13. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
14. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography
15. NKT cells: Facts, functions and fallacies
16. Requirement for membrane lymphotoxin in natural killer cell development
17. Membrane lymphotoxin is required for the development of different subpopulations of NK T cells
18. The Src family tyrosine kinase Fyn regulates natural killer T cell development
19. Cutting edge: NKT cell development is selectively impaired in Fyn-deficient mice
20. Cutting edge: The Ets1 transcription factor is required for the development of NK T cells in mice
21. NK1.1+ T cells in the liver arise in the thymus and are selected by interactions with class I molecules on CD4+CD8+ cells
22. Selection of phenotypically distinct NK1.1+ T cells upon antigen expression in the thymus or in the liver
23. CD1d-glycolipid tetramers: A new tool to monitor natural killer T cells in health and disease
24. Notch1 and T-cell development: Insights from conditional knockout mice
25. NKT cells derive from double-positive thymocytes that are positively selected by CD1d
26. Natural ligand of mouse CD1d1: Cellular glycosylphosphatidyl-inositol
27. Cutting edge: The IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: Exploring the role of GPIs in NK T cell activation and antimalarial responses
28. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides
29. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
30. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis
31. Activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype
32. Activation of acceptor-suppressor hybridoma with antigen-specific suppressor T cell factor of two-chain type: Requirement of the antigen- and the I-J-restricting specificity
33. Sequence and expression of transcripts of the T-cell antigen receptor alpha-chain gene in a functional, antigen-specific suppressor-T-cell hybridoma
34. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3
35. Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production
36. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4
37. Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice
38. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells
39. A molecular analysis of NKT cells: Identification of a class-I restricted T cell-associated molecule (CRTAM)
40. Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta (2)-microglobulin-deficient BALB/c mice
41. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells
42. CD1d on myeloid dendritic cells stimulates cytokine secretion from and cytolytic activity of V alpha 24 J alpha Q T cells: A feedback mechanism for immune regulation
43. Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic activity: An important immune regulatory function
44. Bone marrow NK1.1 (-) and NK1.1 (+) T cells reciprocally regulate acute graft versus host disease
45. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site
46. Immunological characteristics of intragraft NKR-P1+ TCR alpha beta + T (NKT) cells in rat hepatic allografts
47. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance
48. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance
49. MIP-2 recruits NKT cells to the spleen during tolerance induction
50. Immune suppression and skin cancer development: Regulation by NKT cells
51. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
52. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4
53. Natural killer-like T cells develop in SJL mice despite genetically distinct defects in NK1.1 expression and in inducible interleukin-4 production
54. Age-dependent appearance of NK1.1+ T cells in the livers of beta2-microglobulin knockout and SJL mice
55. Regulation of experimental autoimmune encephalomyelitis in the C57BL/6 J Mouse by NK1.1 (+), DX5 (+), alphabeta (+) T Cells
56. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V alpha 14 NK T cells
57. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis
58. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis
59. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells
60. Differential expression of NK T cell V alpha 24 J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy
61. CD1 expression is differentially regulated by microglia, macrophages and T cells in the central nervous system upon inflammation and demyelination
62. Self glycolipids as T-cell autoantigens
63. CD4 (+) T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice
64. Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice
65. Cutting edge: A role for CD1 in the pathogenesis of lupus in NZB/NZW mice
66. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis
67. Increased interleukin-4 production by NK T cells in systemic lupus erythematosus
68. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c
69. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases
70. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d
71. Beta 2-microglobulin-independent MHC class Ib molecule expressed by human intestinal epithelium
72. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice
73. Cd1d-restricted cellular lysis by peripheral blood lymphocytes: Relevance to the inflammatory bowel diseases
74. Circulating V (alpha24+) Vbeta11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage
75. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells
76. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system
77. Selective reduction of T cells bearing invariant V alpha 24 J alpha Q antigen receptor in patients with systemic sclerosis
78. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA)
79. Elevated frequencies of natural killer T lymphocytes in myasthenia gravis
80. NKT-associated markers and perforin in hyperplastic thymuses from patients with Myasthenia gravis
81. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes
82. +-like thymocytes in the NOD mouse
83. Association between alphabetaTCR+CD4-CD8-T-cell deficiency and IDDM in NOD/Lt mice
84. Diabetes prone BB rats are severely deficient in natural killer T cells
85. Heterophile antibodies segregate in families and are associated with protection from type 1 diabetes
86. Multiple differences in gene expression in regulatory Valpha 24Jalpha Q T cells from identical twins discordant for type I diabetes
87. Intrinsic defects in the T-cell lineage results in natural killer T-cell deficiency and the development of diabetes in the nonobese diabetic mouse
88. IL-7 reverses NK1+ T cell-defective IL-4 production in the non-obese diabetic mouse
89. Activation of NKT cells by alpha galactosylceramide treatment prevents the onset and recurrence of autoimmune type I diabetes
90. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in non-obese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus
91. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10
92. Overexpression of natural killer T cells protects Valpha14Jalpha281 transgenic nonobese diabetic mice against diabetes
93. NK T cell-induced protection against diabetes in Valpha14Jalpha281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen
94. Genetic control of autoimmune diabetes in the NOD mouse
95. A 2-Mb YAC contig and physical map of the natural killer gene complex on mouse chromosome 6
96. Protection against diabetes and improved NK/NKT cell performance in NOD.NK1.1 mice congenic at the NK complex
97. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice
98. Damage control, rather than unresponsiveness, effected by protective DX5+ T cells in autoimmune diabetes
99. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse
100. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes
101. Following a diabetogenic T cell from genesis through pathogenesis
102. Prevention of autoimmune diabetes in NOD mice by the natural killer T cell ligand α-galactosylceramide
103. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets
104. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse
105. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
106. Tolerance to islet autoantigens in type 1 diabetes
107. Human CD1d functions as a transplantation antigen and a restriction element in mice
108. Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1.1 depletion
109. Importance of donor-derived lymphocytes in the protection of pancreaticoduodenal or islet grafts from recurrent autoimmunity: A role for RT6+NKR-P1+ T cells
110. CD4 (+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice
111. Combination therapy with cyclosporine and interleukin-4 or interleukin-10 prolongs survival of syngeneic pancreatic islet grafts in nonobese diabetic mice: Islet graft survival does not correlate with mRNA levels of type 1 or type 2 cytokines, or transforming growth factor-beta in the islet grafts
112. + T cells
113. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution